The Food and Drug Administration approved on Wednesday a new pain pill that was created to discourage abuse, the Associated Press reports.
The new pill, Targiniq ER, combines oxycodone, a potentially addictive opioid used in many pain medications, with naloxone, often used to trim the effects of opioids. The naloxone isn’t activated if the pill is swallowed as normal. If a would-be drug abuser crushes the pill to snort or inject it, however, the naloxone activates. That can potentially make Targiniq ER less attractive to abusers.
“Targiniq ER has properties that are expected to deter, but not totally prevent, abuse of the drug by snorting and injection,” FDA said in a statement.
- The Fight to Save the Salmon
- Inside the World of Black Bitcoin, Where Crypto Is About Making More Than Just Money
- The 'Great Resignation' Is Finally Getting Companies to Take Burnout Seriously. Is It Enough?
- Suddenly, Everyone on TV Is Very Rich or Very Poor. What Happened?
- Colin Powell Reflects on His Mistakes in Unpublished TIME Interview
- Business Travel's Demise Could Have Far-Reaching Consequences
- If the U.S. Spends Big on Climate, the Rest of the World Might Follow